Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
The Select study showed that Wegovy reduced the risk ... Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average ... a patient's heart health through methods beyond weight loss, the study authors concluded. Notably, the weight loss ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy ... “This is the longest study we’ve conducted so far of semaglutide for weight loss,” stated Martin Holst Lange, Novo ...
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on ...
LONDON (Reuters) -Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight ... for which substantial results had been published last year. "This is the longest study ...